Make Informed Investment Decisions with Affordable Access to Experts
Evaluating Potential Growth Prospects for Keryx's (KERX) Auryxia After Positive Phase III Data Evaluating Iron Deficiency Anemia Patients (IDA) With Stage 3-5 Non-Dialysis-Dependent Chronic Kidney Disease (NDD CKD)Ticker(s): KERX
Name: Dr Edward Skolnik - MD
- Director of Division of Nephrology, Norman S. Wikler Professor of Medicine & Professor of Pharmacology at NYU Langone.
- In practice for 33 years, double board certified in Nephrology and Internal Medicine, and has extensive experience treating patients with CKD and FSGS.
- Published a number of articles in peer reviewed journals and member of several professional organizations including The American Society for Clinical Investigation
Can you describe your experience treating iron deficiency anemia in adults with non-dialysis dependent chronic kidney disease.? With no FDA approved treatments, what do you currently do to help your patients?Added By: pjloria
How do patients respond to current treatment options, including over the counter iron supplements and intravenous iron (Feraheme or Venofer)? How do these treatments compare to Auryxia?Added By: pjloria
What are the relative benefits of these treatment options? Are some treatment options better fit for certain patient subsets?Added By: pjloria
Given the current data, what are the chances Auryxia is approved for the expanded indication?Added By: pjloria
Data from the ESRD Phase III study showed a 24% reduction in repeat hospitalizations versus then standard of care (presumably due to reduced IV iron use). So why has take-up been so slow? How much is due to formulary access?Added By: mudsharkox
What are the differences in costs between current treatment options and Auryxia?Added By: pjloria
Assuming it gets approved, what percentage of existing patients do you expect to start taking Auryxia? What percentage do you expect to stay on IV iron or supplements? What percentage of new patients do you expect will choose each treatment option?Added By: pjloria
Assuming it gets approved, how will an expanded indication change the perception of the iron black box warning for physicians?Added By: pjloria
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.